Abstract
In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Analysis of Variance
-
Antipsychotic Agents / adverse effects*
-
Benzodiazepines / adverse effects*
-
Depression / drug therapy
-
Depression / genetics
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Combinations
-
Female
-
Fluoxetine / adverse effects*
-
Genome-Wide Association Study / methods
-
Humans
-
Hyperprolactinemia / chemically induced*
-
Hyperprolactinemia / genetics
-
Male
-
Middle Aged
-
Polymorphism, Single Nucleotide / genetics*
-
Prolactin / blood*
-
Receptors, Dopamine D2 / genetics*
-
White People
-
Young Adult
Substances
-
Antipsychotic Agents
-
Drug Combinations
-
Receptors, Dopamine D2
-
olanzapine-fluoxetine combination
-
Fluoxetine
-
Benzodiazepines
-
Prolactin